Table 1.
Clinical characteristics of the study population
| Variable | Type 2 diabetic patients | Non-diabetic subjects | P-value |
|---|---|---|---|
| n (male/female) | 378 (210/168) | 334 (206/128) | 0.098 |
| Duration of diabetes (years) | 14.0 ± 9.5 | ||
| Age (years) | 62.5 ± 11.9 | 48.8 ± 12.8 | < 0.001 |
| Diabetes treatment (D/O/I/I+O)* | 58/203/72/43 | ||
| Body mass index (kg/m2) | 23.4 ± 4.1 | 22.6 ± 3.1 | 0.002 |
| HbA1c (%) | 7.4 ± 1.4 | ||
| Fasting blood glucose (mmol/l) | 8.3 ± 2.7 | 4.9 ± 0.4 | < 0.001 |
| Systolic blood pressure (mmHg) | 131 ± 16.8 | 122 ± 15.7 | < 0.001 |
| Diastolic blood pressure (mmHg) | 74 ± 10.3 | 78 ± 11.3 | < 0.001 |
| Total cholesterol (mmol/l) | 5.3 ± 0.94 | 5.2 ± 0.92 | 0.521 |
| Triglycerides (mmol/l) | 1.52 ± 0.90 | 1 ± 0.74 | < 0.001 |
| High-density lipoprotein cholesterol (mmol/l) | 1.35 ± 0.40 | 1.46 ± 0.37 | 0.001 |
| Low-density lipoprotein cholesterol (mmol/l) | 3.2 ± 0.81 | 3.2 ± 0.85 | 0.809 |
| Serum creatinine (mol/l) | 82 ± 73.5 | 70 ± 14.1 | 0.004 |
Data are n or mean ± sd.
*
D, diet only; O, oral glucose-lowering agents; I, insulin; I+O, insulin and oral glucose-lowering agents.